ACEP ID:
On January 23, 2020, the American College of Emergency Physicians (ACEP) convened a Summit, Addressing the Opioid Stigma in the Emergency Department, gathering a diverse group of organizations and representatives to discuss and share ideas to gain insight into the prevalence, effect and targeted solutions to limit the impact of stigma on the care of ED patients with opioid use disorder (OUD). ACEP is part of a large coalition of national professional organizations that make up the Opioid Response Network (ORN), which is led by the American Academy of Addiction Psychiatry and funded by the Substance Abuse and Mental Health Services Administration.
Objectives for the summit included:
Summit participation included representation from:
Through targeted breakout sessions that developed specific recommendations based on consensus, attendees developed concrete strategies to reduce stigma and improve the experience for ED patients with opioid use. Attendees used stories from ED patients with OUD and recommendations for previously enacted successful strategies from other professional organizations to develop these strategies. Using information from the presentations, panel and breakout sessions, ACEP plans to develop a publication that will describe the conference proceedings and specific recommendations for ED policies, education, strategies to engage hospital leadership, patients and families and future research priorities. A short video featuring interviews with former ED patients with OUD sharing their experiences and strategies to improve care will be highlighted alongside ED physician interviews to convey the impact of Stigma around Opioid Use Disorder in the ED, and the opportunities to improve care.
Funding Language:
Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.